1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsExtracorporeal Membrane Oxygenation (ECMO) Research Program is sponsored by National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI). Supports research on ECMO technologies, including monitoring and digital twin applications.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Universities, Nonprofits, State/local governments. Confirm the full requirements in the official notice before applying.
Extracorporeal Membrane Oxygenation (ECMO) Research Program is funded by National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional) is sponsored by National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI). This Small Business Innovation Research (SBIR) program offers non-dilutive funding to small businesses developing healthcare technologies and services that address health disparities and improve health outcomes for underserved populations. It focuses on commercializing products that can make a measurable impact.
RFA-HL-25-001: Lung Cancer Biomarker Discovery and Validation is sponsored by National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI). RFA-HL-25-001: Lung Cancer Biomarker Discovery and Validation is a grant from the NIH National Heart, Lung, and Blood Institute (NHLBI) that funds research to discover and validate biomarkers for lung cancer detection, diagnosis, prognosis, and treatment response.
Five NHLBI Catalyze Product Definition RFAs — HL-26-016 through HL-26-020 — carry an October 21, 2026 receipt date, budget caps of $300,000 to $400,000 per year, and roughly 8 new awards annually. The science is not the gate. An Accelerator Partner and a 0.25:1 non-federal cost match are, and both take longer to line up than the nine weeks you have left.
Read articlePA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read article